Tumor Cell Or Cancer Cell Patents (Class 435/7.23)
-
Publication number: 20140341912Abstract: The invention provides antibody to canine or feline or equine antigens, e.g., canine CD52, and methods of making and using antibodies as described.Type: ApplicationFiled: January 17, 2014Publication date: November 20, 2014Inventor: Genevieve HANSEN
-
Publication number: 20140341915Abstract: The present invention is concerned with diagnostic methods and means. Specifically, it relates to an antibody which specifically binds to a portion of the extracellular domain of the B7-H6 polypeptide. Moreover, said antibody is provided for use in the treatment or diagnosis of cancer or inflammatory disease. Furthermore, provided are a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer or an inflammatory disease. Further, the present invention concerns a device and a kit for diagnosing cancer or an inflammatory.Type: ApplicationFiled: September 10, 2012Publication date: November 20, 2014Inventors: Adelheid Cerwenka, Gerhard Moldenhauer
-
Publication number: 20140341810Abstract: Provided herein are antagonists or binding agents of an abnormal vasopressin receptor V2 (e.g., AbnV2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor V2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro. The antagonists or binding agents may also be used for treating patients suffering from a cancer expressing the abnormal vasopressin receptor V2, such as small cell lung cancer (SCLC), breast cancer, or ovarian cancer.Type: ApplicationFiled: May 12, 2014Publication date: November 20, 2014Applicant: WOOMERA THERAPEUTICSInventors: William G. North, Roy H.L. Pang
-
Publication number: 20140341892Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.Type: ApplicationFiled: May 19, 2014Publication date: November 20, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Elias LAZARIDES, Catherine Woods, Mark Bernard
-
Publication number: 20140336071Abstract: This disclosure relates to compositions, devices and methods of detecting the presence of molecules and optionally quantifying forces associated with molecular interactions on the surface of cells and other lipids. In certain embodiments, devices disclosed herein can be used to detect forces through cell surface receptors. In other embodiments, the devices can be used to detect the presence or absence of molecules on cells or other particles or detect the changes in cell morphology after ligand receptor binding.Type: ApplicationFiled: September 28, 2012Publication date: November 13, 2014Applicant: EMORY UNIVERSITYInventors: Khalid S. Salaita, Carol Schumacher, Daniel R. Stabley
-
Publication number: 20140335090Abstract: Disclosed are a novel therapeutic agent for cancer such as esophageal squamous cell carcinoma, a method for predicting the prognosis of cancer, and a method for detecting, or predicting the prognosis of, cancer such as esophageal squamous cell carcinoma using a sample that can be collected less invasively. The therapeutic agent for cancer comprises as an effective component an antibody that undergoes antigen-antibody reaction with FGFRL1 to suppress the growth of cancer cells, or an antigen-binding fragment thereof. The method for predicting the prognosis of cancer comprises investigating the expression level of FGFRL1 in a cancer tissue separated from a living body, and, in this method, a high expression level of FGFRL1 indicates poor prognosis.Type: ApplicationFiled: March 30, 2012Publication date: November 13, 2014Applicant: KYOTO UNIVERSITYInventors: Soken Tsuchiya, Gozoh Tsujimoto, Kazuharu Shimizu, Yutaka Shimada, Kazuhiro Tsukada
-
Publication number: 20140335107Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: March 19, 2014Publication date: November 13, 2014Applicant: GENENTECH, INC.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson
-
Publication number: 20140335533Abstract: This specification relates to Formalin-fixed embedded quality control material for use for validation, verification, and to run controls for molecular assays. The quality control material can be used for a variety of tissues and for a variety of molecular assays. The quality control material can be used in commercial labs for validation and limit-of-detection analyses.Type: ApplicationFiled: July 24, 2014Publication date: November 13, 2014Inventors: Jerry BOONYARATANAKORNKIT, Erhard SCHOENBRUNNER, Mona SHAHBAZIAN
-
Publication number: 20140336073Abstract: A method for determining the sensitivity and/or resistance of a patient suffering from a cancer disease to Aurora kinase inhibitor therapy, which comprises determining in vitro in the cancer cells or body fluids taken from the patient the expression of at least one gene selected from a particular group and/or determining in vitro in the cancer cells or body fluids taken from the patient the level of at least one protein selected from a particular group.Type: ApplicationFiled: December 7, 2012Publication date: November 13, 2014Applicants: PALACKY UNIVERSITY, OLOMOUC, INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS ASCR, V.V.I.Inventors: Madhusudhan Reddy Kollaredy, Marian Hajduch, Petr Dzubak, Josef Srovnal, Rita Hrabakova, Hana Kovarova
-
Publication number: 20140335541Abstract: Methods of determining prognosis of a subject with cancer or determining risk of cancer progression by assessing expression of B7-H4, or B7-H1 and B7-H4 in combination.Type: ApplicationFiled: July 10, 2014Publication date: November 13, 2014Inventors: Eugene D. Kwon, John C. Cheville, Amy Krambeck, Susan M. Harrington, Robert H. Thompson, Lieping Chen, Haidong Dong, Christine M. Lohse
-
Patent number: 8883497Abstract: Provided herein are methods for determining the presence of cancer (malignant versus benign), monitoring the progression of cancer, monitoring cancer relapse, monitoring the response to cancer therapy, or cancer staging in a subject, by evaluating CD33+/HLA-DRlow, CD14+/HLA-DRlow, CD66b+/HLA-DRlow or, CD11b+/HLA-DRlow MDSC for activation of a transcription factor. Transcription factors include, but are not limited to, STAT3, pSTAT3, HIF1?, or C/EBP?. The MDSC phenotype can be CD33+HLA-DRlowHIF1?+/STAT3+, CD14+HLA-DRlowHIF1?+/STAT3+/pSTAT3+/C/EBPb+, CD66b+HLA-DRlowHIF1?+/STAT3+/pSTAT3+/C/EBPb+, CD33+HLA-DRlowHIF1?+/STAT3+/pSTAT3+/C/EBPb+, CD11b+HLA-DRlowHIF1?+/STAT3+/pSTAT3+/C/EBPb+, or CD11b+HLA-DRlowC/EBP?+. Also provided herein are methods for inducing human MDSC from healthy donor peripheral blood mononuclear cells (PBMC) by co-culturing PBMC with human solid tumor cell lines and subsequently measuring their suppressive ability.Type: GrantFiled: April 27, 2012Date of Patent: November 11, 2014Assignee: University of Southern CaliforniaInventors: Alan L. Epstein, Melissa G. Lechner
-
Patent number: 8883491Abstract: The present invention generally relates to systems and methods for counting biomolecules or cells. In certain embodiments, the invention provides a cell counting or biomolecule counting system including: a covered chamber having a known height and configured to hold a suspension of biomolecules or cells in a sample; at least one fluorescent light source connected to at least one fluorescent light beam narrowing device; a bright-field light source connected to a bright-field light beam narrowing device; a microscope objective; a detection device; a fluorescent filter assembly to allow only excitation light to illuminate the sample and allow only emission light from the sample to be imaged by the detection device; and a movable light shutter to block bright-field light during fluorescent detection.Type: GrantFiled: April 8, 2009Date of Patent: November 11, 2014Assignee: Nexcelom Bioscience LLCInventors: Bo Lin, Peter Y. Li, Jean Qiu, Timothy Smith, Todd Sobolewski, Alnoor Pirani
-
Publication number: 20140329225Abstract: Provided are methods for detecting a target molecule or particle suspected to be present in a sample, comprising (a) contacting the sample with (i) a fusion molecule comprising a ligand capable of binding to the target molecule or particle and a binding domain, and (ii) a polymer scaffold comprising at least one binding motif to which the binding domain is capable of binding, under conditions that allow the target molecule or particle to bind to the ligand and the binding domain to bind to the binding motif; (b) loading the polymer into a device comprising a pore that separates an interior space of the device into two volumes, and configuring the device to pass the polymer through the pore from one volume to the other volume, wherein the device further comprises a sensor adjacent to the pore configured to identify objects passing through the pore; and (c) determining, with the sensor, whether the fusion molecule or particle bound to the binding motif is bound to the target molecule or particle, thereby detectType: ApplicationFiled: May 5, 2014Publication date: November 6, 2014Inventor: Trevor J. Morin
-
Publication number: 20140329248Abstract: Methods of determining prognosis of a subject with cancer by assessing expression of B7-H1 and survivin in combination.Type: ApplicationFiled: July 10, 2014Publication date: November 6, 2014Inventors: Eugene D. Kwon, John C. Cheville, Amy Krambeck, Susan M. Harrington, Robert H. Thompson, Haidong Dong, Christine M. Lohse, Alexander S. Parker
-
Publication number: 20140328751Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: April 9, 2014Publication date: November 6, 2014Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Ole Petter Veiby, John S. Babcook
-
Publication number: 20140329249Abstract: A method of individually releasing from an entity one or more members of a sub-group of biological units included in a heterogeneous group of biological units is provided. The method includes binding the group of biological units including the sub-group of biological units to the entity via a linker. Following binding, the location of the one or more members on the entity is determined. Once the location is determined, a localized physical pulse is applied to the one or more members. The localized physical pulse individually releases the one or more members from the entity by dissociating the linker.Type: ApplicationFiled: April 25, 2014Publication date: November 6, 2014Applicant: Roche Molecular Systems, Inc.Inventors: Judith Brand-Meier, Claudio Cherubini, Andreas Drechsler, Nicole Gwerder, Martin Kopp, Edwin Oosterbroek, Emad Sarofim
-
Publication number: 20140329917Abstract: Apparatus, systems and methods are provided for the identification of various objects, particularly circulating tumor cells. In one aspect the system includes, but is not limited to, a scanning system, an image storage system, and an analysis system. The analysis system preferably identifies desired objects, such as complete cells, based on various criteria, which may include cell nuclear area or volume, CD-45 negative status, and cytokeratine positive status. Preferably included is a slide for containing the cells during the imaging step, the well including a planar bottom surface, a border at the periphery of the well defining sides for the well, the border being adjacent the bottom surface of the well and providing a fluidic seal there between. The invention herein provides for a single imaging well, providing for substantially a monolayer of objects, e.g., cells.Type: ApplicationFiled: December 7, 2012Publication date: November 6, 2014Inventors: Gerd Marienfeld, Peter Kuhn, Anand Kolatkar, Dena Marrinucci
-
Publication number: 20140328830Abstract: The current invention provides human variable chain framework regions and humanized antibodies comprising the framework regions, the antibodies being specific for integrin ?1. The invention also provides methods for utilizing the antibodies, for example to treat diseases such as cancer.Type: ApplicationFiled: December 24, 2013Publication date: November 6, 2014Applicant: ONCOSYNERGY, INC.Inventor: W. Shawn Carbonell
-
Publication number: 20140328758Abstract: The present invention relates to diagnostic imaging and in particular to the diagnostic imaging and therapy of cancer by means of compositions which specifically target the FSH Receptor expressed by tumor endothelial cells and circulating blood cells.Type: ApplicationFiled: July 17, 2014Publication date: November 6, 2014Inventors: NICOLAE GHINEA, AURELIAN RADU
-
Publication number: 20140322131Abstract: The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.Type: ApplicationFiled: July 18, 2014Publication date: October 30, 2014Inventors: Kuo-Jang Kao, Andrew T. Huang
-
Publication number: 20140322234Abstract: ROR2 is provided as a therapeutic target and prognostic marker for cancers, which include without limitation specific carcinomas and sarcomas. This invention also provides for the use of conjugates comprising an antibody that recognizes and binds ROR2, and a cytotoxic agent. In the cytotoxic conjugates, the cell binding agent has a high affinity for ROR2 and the cytotoxic agent has a high degree of cytotoxicity for cells expressing ROR2, such that the cytotoxic conjugates of the present invention form effective killing agents. In a preferred embodiment, the cell binding agent is an anti-ROR2 antibody or an epitope-binding fragment thereof, more preferably a humanized anti-ROR2 antibody or an epitope-binding fragment thereof, wherein a cytotoxic agent is covalently attached, directly or via a cleavable or non-cleavable linker, to the antibody or epitope-binding fragment thereof.Type: ApplicationFiled: January 3, 2013Publication date: October 30, 2014Inventors: Roeland Nusse, Jan Matthijs Van de Rijn, Badreddin Edris
-
Publication number: 20140322356Abstract: Embodiments of the present invention concern methods related to treating, prognosticating and/or diagnosing at least brain metastatic breast cancer. Embodiments of the methods include characterizing circulating tumor cells for the presence or absence of EpCAM and, upon identification of EpCAM negative cells and identification of the status of other markers (such as heparanase and/or Notch1, for example), treating the individual based on the determination of the characterization.Type: ApplicationFiled: November 28, 2012Publication date: October 30, 2014Applicant: BAYLOR COLLEGE OF MEDICINEInventors: Dario Marchetti, Lon Ridgway, Lixin Zhang
-
Publication number: 20140323595Abstract: We describe a method of monitoring the state of a cell, tissue, organ or organism. The method comprises establishing, for a sample of microparticles from the cell, tissue, organ or organism, a ratio. The ratio is of a selected polypeptide in microparticles which comprise GM1 gangliosides, preferably which bind to Cholera Toxin B (CTB) (“GM1 ganglioside microparticle polypeptide”) to the selected polypeptide in microparticles which comprise exposed phosphotidylserine, preferably which bind to Annexin V (“Annexin V microparticle polypeptide”). The GM1 ganglioside microparticle polypeptide to Annexin V microparticle polypeptide ratio so established may be indicative of the state of the cell, tissue, organ or organism.Type: ApplicationFiled: November 30, 2012Publication date: October 30, 2014Inventors: Sai Kiang Lim, Kok Hian Tan
-
Publication number: 20140322129Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: March 13, 2014Publication date: October 30, 2014Applicant: Genentech, Inc.Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
-
Publication number: 20140314675Abstract: An objective of the present invention is to provide: a cancer stem cell isolated using a cell marker; a substantively homogeneous cancer stem cell population including said cancer stem cell; and a method of preparing said cancer stem cell population. Another objective of the present invention is to provide: a method for separating cancer stem cells with a high proliferative potential and those with a low proliferative potential; a method for inducing cancer stem cells to have a different proliferative potential; and cancer stem cells separated or induced by these separation or induction methods. A further objective of the present invention is to provide: a method of screening for pharmaceuticals using said cancer stem cell or cancer stem cell population; a method for detecting the presence of said cancer stem cell or cancer stem cell population and for identifying or quantifying the same.Type: ApplicationFiled: September 7, 2012Publication date: October 23, 2014Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20140314766Abstract: Aspects of the present invention provide novel Mig-7 encoding nucleic acids and Mig-7 polypeptides, recombinant DNA expression systems and host cells containing same, as well as methods of inhibiting expression of the subject nucleic acid molecules, inhibiting production of the encoded proteins or polypeptides, inhibiting metastasis of a carcinoma cell in a subject (including in humans), inhibiting migration/invasion of and mimicking of normal cells by carcinoma cells in a subject, detecting the presence of a cancer cell (e.g., a migrating/invading cancer cell or carcinoma cell mimic, and tumor neovascularization) in a sample of a subject's tissue or body fluids, and inhibiting the migration/invasion of or endothelial cell mimicking by a placental cell into the blood stream or vessels of a female mammal.Type: ApplicationFiled: May 8, 2014Publication date: October 23, 2014Inventor: J. Suzanne Lindsey
-
Publication number: 20140314742Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.Type: ApplicationFiled: October 15, 2013Publication date: October 23, 2014Applicant: TRACON PHARMACEUTICALS, INC.Inventors: Charles Theuer, Maximiliano Vasquez
-
Publication number: 20140315741Abstract: This document relates to methods and materials involved in modulating deubiquitinases (e.g., USP10 polypeptides) and/or ubiquitinated polypeptides (e.g., tumor suppressor polypeptides or mutant versions of tumor suppressor polypeptides). For example, methods and materials for increasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for decreasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for stabilizing tumor suppressor polypeptides (e.g., wild-type p53 polypeptides), methods and materials for de-stabilizing mutant versions of tumor suppressor polypeptides (e.g., mutant p53 polypeptides), and methods and materials for reducing cancer cell proliferation, increasing cancer cell apoptosis, and/or treating cancer (e.g., cancers having reduced levels of wild-type p53 polypeptides or cancers having increased levels of mutant p53 polypeptides) are provided.Type: ApplicationFiled: July 1, 2014Publication date: October 23, 2014Inventors: Zhenkun Lou, Jian Yuan
-
Publication number: 20140315929Abstract: This invention concerns a method for selecting an inhibitor of a cancer-implicated pathway or of a component of a cancer-implicated pathway for coadministration, with an inhibitor of HSP90, to a subject suffering from a cancer which comprises the following steps: (a) contacting a sample containing cancer cells from a subject with an inhibitor of HSP90 or an analog, homolog or derivative of an inhibitor of HSP90 under conditions such that one or more cancer pathway components present in the sample bind to the HSP90 inhibitor or the analog, homolog or derivative of the HSP90 inhibitor; (b) detecting pathway components bound to the HSP90 inhibitor or to the analog, homolog or derivative of the HSP90 inhibitor; (c) analyzing the pathway components detected in step (b) so as to identify a pathway which includes the components detected in step (b) and additional components of such pathway; and (d) selecting an inhibitor of the pathway or of a pathway component identified in step (c).Type: ApplicationFiled: April 27, 2012Publication date: October 23, 2014Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventor: Gabriela Chiosis
-
Publication number: 20140315220Abstract: Disclosed are conjugates that can bind to one or more site on cancer cell surface, for example, surface proteins, compound specific receptors and carbohydrates that comprise the surface of specific cell types. The disclosed conjugates can thereby serve as indicators identifying the presence of cancerous tissue.Type: ApplicationFiled: July 20, 2012Publication date: October 23, 2014Applicant: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Chaofeng Dai, Binghe Wang, Lifang Wang, Yong Chu
-
Patent number: 8865420Abstract: The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations.Type: GrantFiled: May 22, 2008Date of Patent: October 21, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Omar D. Perez, Garry P. Nolan, Jonathan M. Irish
-
Patent number: 8865413Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.Type: GrantFiled: May 4, 2011Date of Patent: October 21, 2014Assignee: Celera CorporationInventors: Bruno Domon, Ian McCaffery, Vaibhav Narayan, Scott Patterson
-
Publication number: 20140308202Abstract: The present invention is drawn to methods of assessing hormonally-regulated cancers such as prostate and breast, by examining the expression of particular genes disregulated in this disease state.Type: ApplicationFiled: April 11, 2014Publication date: October 16, 2014Applicant: VANDERBILT UNIVERSITYInventors: Robert J. Matusik, Renjie Jin, Yajun YI, Fiona E. YULL, Timothy S. Blackwell, Peter E. CLARK, Joseph A. SMITH
-
Publication number: 20140308301Abstract: Compositions including an antibody specific for CD44 are provided. These antibodies specifically bind to hematologic malignant cells. Methods to use the CD44 antibodies to target cells expressing CD44 for therapeutic and diagnostic purposes are also provided.Type: ApplicationFiled: October 26, 2012Publication date: October 16, 2014Inventors: Thomas J. Kipps, Suping Zhang, Christina C. Wu
-
Publication number: 20140308669Abstract: The present application provides methods for obtaining single cells from a sample. Methods for isolating and analyzing molecular features obtained from a single cell are also disclosed herein. For example, individual circulating tumor cells (CTCs) from a sample such as a patient's blood sample can be identified and obtained using methods disclosed herein, and picked for further analysis.Type: ApplicationFiled: January 23, 2012Publication date: October 16, 2014Applicant: Epic Science, Inc.Inventors: Xing Yang, David M. Nelson, Peter Kuhn, Daniel Chesnaye Lazar
-
Publication number: 20140309263Abstract: The present invention relates to methods of diagnosing a kidney disorder in a patient, as well as methods of monitoring the progression of a kidney disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.Type: ApplicationFiled: January 31, 2014Publication date: October 16, 2014Applicant: MESO SCALE TECHNOLOGIES, LLCInventors: Simone Barbero, Eli N. Glezer, Anu Mathew, Mingyue Wang
-
Publication number: 20140308294Abstract: The invention relates to polypeptides that block or inhibit the interleukin-1 receptor 1 (IL-1R1), the interaction of IL-1beta with IL-1R1 or the interaction between IL-1R1 and interleukin-1 receptor accessory protein (IL-1RaCP). The invention relates specifically to therapeutic polypeptides that target specifically IL-1R1 present on tumor cells, cancer stem cells, and cancer stem cells which are resistant to chemotherapy or radiotherapy. The invention specifically relates to cancer stem cells (CSC) that express IL-1R1 to which said inhibitors bind. Finally the invention relates to a combination therapy comprising killing tumorigenic differentiating cancer cells by means of standard chemo- or radiotherapy and prior or subsequent to that applying IL-1R1 inhibitors which target specifically CSC and strip the tumor of its capacity to generate cancer cell progeny.Type: ApplicationFiled: April 13, 2012Publication date: October 16, 2014Applicant: MERCK PATENT GMBHInventors: Anita Seshire, Michael Wolf, Robert Tighe, Helen Sabzevari
-
Patent number: 8859213Abstract: The invention provides a method for diagnosing a melanocytic proliferation in a subject comprising staining a sample of lesional melanocytes with an antibody against soluble adenylyl cyclase (sAC) and interpreting the sAC staining pattern, which is associated with a diagnosis of a melanocytic proliferation. The sAC staining pattern, which is complex, is discriminatory and distinctive according to the nature of the melanocytic proliferation. The sAC staining pattern comprises one or more of dot-like Golgi staining, broad granular Golgi staining, diffuse cytoplasmic staining, nucleolar staining, incomplete granular nuclear staining, and pan-nuclear staining. The method of the invention is particularly useful in confirming or disaffirming a diagnosis reached through conventional histologic examination of a sample. Additionally, the invention provides a kit for use in interpreting melanocytic proliferations.Type: GrantFiled: April 6, 2011Date of Patent: October 14, 2014Assignee: Cornell UniversityInventors: Cynthia Magro, Jonathan Zippin, Lonny R. Levin, Jochen Buck
-
Publication number: 20140302041Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.Type: ApplicationFiled: June 22, 2012Publication date: October 9, 2014Applicants: ORIBASE PHARMA, Institut Regional du Cancer de Montpellier-Val d' Aurelle, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
-
Publication number: 20140303002Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.Type: ApplicationFiled: March 21, 2014Publication date: October 9, 2014Applicant: Genomic Health, Inc.Inventors: Steven Shak, Mark Lee, William F. Novotny, Tara Maddala, Michael R. Crager, Diana Cherbavaz, Robert J. Pelham, Carl L. Millward, Dejan Knezevic
-
Publication number: 20140303026Abstract: The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.Type: ApplicationFiled: June 20, 2014Publication date: October 9, 2014Inventors: Vineet Gupta, M. Amin Arnaout
-
Publication number: 20140302511Abstract: An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective of the present invention is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.Type: ApplicationFiled: October 26, 2012Publication date: October 9, 2014Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Osamu Natori, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20140302529Abstract: A filter element (200) and a method are disclosed for retaining particles of a medium, for example (rare) cells of blood. The filter element (200) comprises at least one opening (220) that (i) has an elongate cross section and/or (ii) has a cross section that decreases in flow direction (x) and/or (iii) is bordered by a transparent wall. Preferably, the filter element (100, 200, 300) is provided with a plurality of elongate openings (220) of stepwise decreasing cross section that are arranged on a common transparent slide. Thus high flow rates can be realized throughout the filtering process, and the retained particles are immediately ready for visual inspection without a need for a further transfer.Type: ApplicationFiled: October 24, 2012Publication date: October 9, 2014Inventors: Reinhold Wimberger-Friedl, Anja Van De Stolpe, Freek Van Hemert
-
Publication number: 20140303191Abstract: Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.Type: ApplicationFiled: October 19, 2012Publication date: October 9, 2014Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
-
Publication number: 20140302026Abstract: The present invention is concerned with a protein oligomer comprising at least two NC-1 monomers of human collagen 18 or fragments of an NC-1 monomer of human collagen 18 for use in the treatment or prevention of an angiogenesis-related disease. The invention further pertains to a fusion protein comprising a NC-1 monomer of human collagen 18 and a Fc domain of an immunoglobulin. The invention also relates to a fusion protein comprising: a) an endostatin peptide or endostatin-derived peptide and b) the RGD motif and/or PHSRN motif of Fibronectin. The invention further relates to a kit comprising the protein oligomer or fusion proteins of the invention.Type: ApplicationFiled: August 23, 2012Publication date: October 9, 2014Applicant: Deutsches KrebsforschungszentrumInventors: Tong-Young Lee, Amir Abdollahi, Kashi Javaherian
-
Patent number: 8852870Abstract: Methods for diagnosing a cancer in a subject are provided that include determining an amount of autoantibodies immunoreactive to procathepsin D (pCD) in a sample obtained from the subject. Further provided are systems for diagnosing a cancer in a subject that include an autoantibody immunoreactive pCD antigen and a means for detecting binding of an autoantibody to the antigen.Type: GrantFiled: June 16, 2009Date of Patent: October 7, 2014Assignee: University of Louisville Research Foundation, Inc.Inventors: Vaclav Vetvicka, Martin Fusek, Jarmila Zidkova
-
Patent number: 8852592Abstract: The present invention is related to the anti-PAX8 antibodies, kits, cocktails, and use of anti-PAX8 antibodies for detection of cancer.Type: GrantFiled: May 10, 2012Date of Patent: October 7, 2014Assignee: Biocare Medical, LLCInventors: Weimin Qi, David Tacha
-
Publication number: 20140294765Abstract: This invention relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for LSR molecules, which are suitable drugs for immunotherapy and treatment of specific cancer.Type: ApplicationFiled: June 19, 2013Publication date: October 2, 2014Applicant: COMPUGEN LTD.Inventors: Gad S. Cojocaru, Liat Dassa, Galit Rotman, Ofer Levi, Andrew Pow, Shirley Sameach-Greenwald, Zurit Levine
-
Publication number: 20140295460Abstract: Determining a presence of a target analyte in a fluid sample includes mixing multiple magnetic particles with the fluid sample, in which the magnetic particles are each bound to one or more binding moieties that specifically bind to the target analyte, flowing the fluid sample containing the magnetic particles through a fluidic channel, exposing the fluid sample in the fluidic channel to a magnetic field, measuring a signal from a Hall effect sensor while the fluid sample flows through the fluidic channel, and determining whether the target analyte is present in the fluid sample when the measured signal is in a first range of values.Type: ApplicationFiled: November 21, 2012Publication date: October 2, 2014Applicant: The General Hospital CorporationInventors: Ralph Weissleder, Hakho Lee, David Issadore
-
Publication number: 20140294729Abstract: The invention relates to methods for identifying compounds and compositions that target cancer stem cells. In some aspects, the invention relates to treatment methods that use compounds and compositions that specifically target cancer stem cells for inhibiting the growth and/or survival of cancer stem cells in a subject in need thereof. Other aspects of the invention relate to the use of cancer stem cell biomarkers in the selection of a treatment for inhibiting the growth and/or survival of cancer stem cells in a subject in need thereof.Type: ApplicationFiled: October 28, 2013Publication date: October 2, 2014Applicants: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, President and Fellows of Harvard CollegeInventors: PIYUSH GUPTA, TAMER T. ONDER, ERIC S. LANDER, ROBERT A. WEINBERG, SENDURAI MANI, MAI-JING LIOA